Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Blocking the prion-like disease propagation in Parkinson’s disease and related disorders – model development and identification of cell-autonomous and cell non-autonomous factors.

Description du projet

Révéler la nature «prion-like» de la maladie de Parkinson: un changement de paradigme

Les mouvements incontrôlables caractéristiques de la maladie de Parkinson (MP) résultent d’une dégénérescence neuronale chronique. L’accumulation d’agrégats de la protéine alpha-synucléine (AS) est l’une des caractéristiques de la physiopathologie de la maladie de Parkinson. Financé par le programme Actions Marie Skłodowska-Curie, le projet Alpha-Synuclein part de l’hypothèse que l’AS se comporte comme un prion, se propageant du système nerveux périphérique au système nerveux central, ce qui exacerbe le stress oxydatif et le dysfonctionnement et mène à la perte de neurones dans le cerveau. Pour prévenir cette neurotoxicité et cette dégénérescence, les chercheurs suggèrent de créer un nouveau modèle d’étude de la propagation de l’AS, en se concentrant sur le rôle de gènes spécifiques dans la propagation et la toxicité de l’AS.

Objectif

A prion-like behavior of α-synuclein (AS) protein has been hypothesized in the pathogenesis of Parkinson disease (PD). According to this hypothesis, pathogenic forms “seeds” of AS propagate from periphery into the neurons of central nervous system (CNS), where they recruit endogenous AS in the first receiving neurons, exit the cell and enter connected neurons. The ongoing AS aggregation and cell-cell propagation is considered to induce oxidative stress, neuronal dysfunction and neuronal loss in CNS. Therefore, blocking the neuronal propagation of AS will prevent AS neurotoxicity and neurodegeneration. I propose to develop and validate a novel in vivo model of prion-like AS propagation, in which I will selectively modify the genetic makeup of first receiving neurons, and use this model for mechanistic investigations. I will use a transgenic M83 mouse model overexpressing mutant A53T human AS in which prion-like spreading is initiated by injecting preformed AS aggregates into the hindlimb musculus femoris. These AS aggregates are taken up by sensory and/or motor nerve endings in the muscle, are retrogradely transported through the sciatic nerve into spinal cord, and rostrally into the brainstem and higher brain areas over time. I will refine this model by transducing the sciatic nerve endings with intramuscular delivery of rAAV viral vectors- containing novel CRISPR/Cas9 genome editing tools targeting genes of interest- to prevent in vivo prion-like AS spreading and/or toxicity. As proof of concept, I will silence AS in the receiving neurons to demonstrate this slows the disease development in the model. Once validated, I will use the model for hypothesis-driven mechanistic investigations of candidate genes, which initially include: 1) ubiquitin specific peptidase 19 (USP19)- since it has been implicated in cellular excretion of misfolded AS in vitro, and 2) eukaryotic elongation factor-2 kinase (eEF2K)- since it is abnormally activated in postmortem PD brain tissue.

Champ scientifique (EuroSciVoc)

CORDIS classe les projets avec EuroSciVoc, une taxonomie multilingue des domaines scientifiques, grâce à un processus semi-automatique basé sur des techniques TLN. Voir: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

Vous devez vous identifier ou vous inscrire pour utiliser cette fonction

Régime de financement

MSCA-IF-EF-ST - Standard EF

Coordinateur

AARHUS UNIVERSITET
Contribution nette de l'UE
€ 200 194,80
Coût total
€ 200 194,80